Séverine Valmary-Degano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Séverine Valmary-Degano has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Claire Illac
Department of Pathology, Claudius Regaud Institute, IUTC Oncopôle, Toulouse
4 shared publications - Nazim Benzerdjeb
Department of Pathology, Institut of Pathologie Multisite, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France; Gustave Roussy, Villejuif, France
3 shared publications - Peggy Dartigues
Département de biologie et de pathologie médicales, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France
3 shared publications Amal Fekkar
CHU Grenoble-Alpes, Department of Pathology, 38043, Grenoble, France
2 shared publications- Anne Chevallier
Department of Pathology, CHU l'Archet, Nice
2 shared publications - Anne Mc Leer
Univ Grenoble Alpes, Grenoble, France
2 shared publications
Latest Publications
- 5 August 2025
- Published by Elsevier in Annales de Pathologie
- Vol. 45 (5) , 438-442
Angiome splénique à cellules littorales et syndrome d’Epstein
- 5 August 2025
- Published by Elsevier in Annales de Pathologie
- Vol. 45 (5) , 438-442
Angiome splénique à cellules littorales et syndrome d’Epstein
- 1 August 2025
[Littoral cell angioma of the spleen and Epstein syndrome].
We report the case of a 24-year-old patient affected by Epstein syndrome, in whom a CT scan performed in a traumatic context revealed numerous splenic lesions. After hemostatic splenectomy, the pathological examination showed splenic well-limited, non-encapsulated nodules, consisting of dilated venous sinuses, filled with red blood cells with inter-connected anfractuous vascular structures. These lesions had the following double endothelial and histiocytic immunohistochemical profile: CD31+, Factor VIII+, CD34+, ERG+, D2/40-, CD68+, CD21+/-. This is the second case reported in the literature of littoral cell angioma in association with Epstein syndrome.
- 1 August 2025
[Littoral cell angioma of the spleen and Epstein syndrome].
We report the case of a 24-year-old patient affected by Epstein syndrome, in whom a CT scan performed in a traumatic context revealed numerous splenic lesions. After hemostatic splenectomy, the pathological examination showed splenic well-limited, non-encapsulated nodules, consisting of dilated venous sinuses, filled with red blood cells with inter-connected anfractuous vascular structures. These lesions had the following double endothelial and histiocytic immunohistochemical profile: CD31+, Factor VIII+, CD34+, ERG+, D2/40-, CD68+, CD21+/-. This is the second case reported in the literature of littoral cell angioma in association with Epstein syndrome.
- Open Access
- 20 February 2025
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 49 (5) , 499-507
Insights into the Clinical Prognosis of High-grade Appendiceal Mucinous Neoplasms
High-grade appendiceal mucinous neoplasm (HAMN) is used to describe a rare epithelial neoplasm of the appendix characterized by pushing-type invasion and high-grade cytologic atypia. Its implications regarding lymph node spread and the necessity of right colectomy are currently debate. The objective of the present study was to assess the clinicopathologic characteristics, the risk of lymph node and peritoneal metastasis, and long-term outcomes of patients diagnosed as HAMN in comparison to low-grade appendiceal mucinous neoplasm (LAMN) and appendiceal adenocarcinoma, treated by right hemicolectomy. A total of 443 patients diagnosed with LAMN (n=246), HAMN (n=34), or appendiceal adenocarcinoma (n=163) and who underwent right colectomy with lymph node dissection in all cases within 32 institutions of the French Network for Rare Peritoneal Malignancies (RENAPE) were included. The median age was 56.5 years (range: 21 to 91), and the majority were female (n=250, 56.4%) without difference between groups (P=0.604). Lymph node metastases were identified in 17.8% of appendiceal adenocarcinoma cases (29/163); none were found among LAMN or HAMN cases. A higher number of lymph nodes were analyzed in those treated for appendiceal adenocarcinoma than LAMN (PP=0.035). Regarding peritoneal metastasis, a higher proportion of cases were classified as high-grade with/without signet cells in patients treated for HAMN (PPPPP=0.042) and PFS (P=0.012) than those treated for appendiceal adenocarcinoma. No lymph node metastases were observed in patients treated for HAMN, and those without appendix perforation had a similar prognosis to LAMN. This study supports staging HAMN using the same system as LAMN and treating it with appendectomy alone in the absence of appendix perforation.
- 20 February 2025
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 49 (5) , 499-507
Open AccessInsights into the Clinical Prognosis of High-grade Appendiceal Mucinous Neoplasms
High-grade appendiceal mucinous neoplasm (HAMN) is used to describe a rare epithelial neoplasm of the appendix characterized by pushing-type invasion and high-grade cytologic atypia. Its implications regarding lymph node spread and the necessity of right colectomy are currently debate. The objective of the present study was to assess the clinicopathologic characteristics, the risk of lymph node and peritoneal metastasis, and long-term outcomes of patients diagnosed as HAMN in comparison to low-grade appendiceal mucinous neoplasm (LAMN) and appendiceal adenocarcinoma, treated by right hemicolectomy. A total of 443 patients diagnosed with LAMN (n=246), HAMN (n=34), or appendiceal adenocarcinoma (n=163) and who underwent right colectomy with lymph node dissection in all cases within 32 institutions of the French Network for Rare Peritoneal Malignancies (RENAPE) were included. The median age was 56.5 years (range: 21 to 91), and the majority were female (n=250, 56.4%) without difference between groups (P=0.604). Lymph node metastases were identified in 17.8% of appendiceal adenocarcinoma cases (29/163); none were found among LAMN or HAMN cases. A higher number of lymph nodes were analyzed in those treated for appendiceal adenocarcinoma than LAMN (PP=0.035). Regarding peritoneal metastasis, a higher proportion of cases were classified as high-grade with/without signet cells in patients treated for HAMN (PPPPP=0.042) and PFS (P=0.012) than those treated for appendiceal adenocarcinoma. No lymph node metastases were observed in patients treated for HAMN, and those without appendix perforation had a similar prognosis to LAMN. This study supports staging HAMN using the same system as LAMN and treating it with appendectomy alone in the absence of appendix perforation.
- 29 May 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (5) , 372-377
Carcinome médullaire rénal SMARCB1-déficient révélé par une métastase ganglionnaire sus-claviculaire
- 29 May 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (5) , 372-377
Carcinome médullaire rénal SMARCB1-déficient révélé par une métastase ganglionnaire sus-claviculaire
- 22 May 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 237-244
Histoséminaire biopsies péritonéales tumorales. Cas no 1
- 22 May 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 237-244
Histoséminaire biopsies péritonéales tumorales. Cas no 1
- Open Access
- 13 March 2024
- Published by MDPI AG in BioMedInformatics
- Vol. 4 (1) , 823-836
Overall Survival Time Estimation for Epithelioid Peritoneal Mesothelioma Patients from Whole-Slide Images
Background: The advent of Deep Learning initiated a new era in which neural networks relying solely on Whole-Slide Images can estimate the survival time of cancer patients. Remarkably, despite deep learning’s potential in this domain, no prior research has been conducted on image-based survival analysis specifically for peritoneal mesothelioma. Prior studies performed statistical analysis to identify disease factors impacting patients’ survival time. Methods: Therefore, we introduce MPeMSupervisedSurv, a Convolutional Neural Network designed to predict the survival time of patients diagnosed with this disease. We subsequently perform patient stratification based on factors such as their Peritoneal Cancer Index and on whether patients received chemotherapy treatment. Results: MPeMSupervisedSurv demonstrates improvements over comparable methods. Using our proposed model, we performed patient stratification to assess the impact of clinical variables on survival time. Notably, the inclusion of information regarding adjuvant chemotherapy significantly enhances the model’s predictive prowess. Conversely, repeating the process for other factors did not yield significant performance improvements. Conclusions: Overall, MPeMSupervisedSurv is an effective neural network which can predict the survival time of peritoneal mesothelioma patients. Our findings also indicate that treatment by adjuvant chemotherapy could be a factor affecting survival time.
- 13 March 2024
- Published by MDPI AG in BioMedInformatics
- Vol. 4 (1) , 823-836
Open AccessOverall Survival Time Estimation for Epithelioid Peritoneal Mesothelioma Patients from Whole-Slide Images
Background: The advent of Deep Learning initiated a new era in which neural networks relying solely on Whole-Slide Images can estimate the survival time of cancer patients. Remarkably, despite deep learning’s potential in this domain, no prior research has been conducted on image-based survival analysis specifically for peritoneal mesothelioma. Prior studies performed statistical analysis to identify disease factors impacting patients’ survival time. Methods: Therefore, we introduce MPeMSupervisedSurv, a Convolutional Neural Network designed to predict the survival time of patients diagnosed with this disease. We subsequently perform patient stratification based on factors such as their Peritoneal Cancer Index and on whether patients received chemotherapy treatment. Results: MPeMSupervisedSurv demonstrates improvements over comparable methods. Using our proposed model, we performed patient stratification to assess the impact of clinical variables on survival time. Notably, the inclusion of information regarding adjuvant chemotherapy significantly enhances the model’s predictive prowess. Conversely, repeating the process for other factors did not yield significant performance improvements. Conclusions: Overall, MPeMSupervisedSurv is an effective neural network which can predict the survival time of peritoneal mesothelioma patients. Our findings also indicate that treatment by adjuvant chemotherapy could be a factor affecting survival time.
- 27 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 230-231
Histoséminaire biopsies du péritoine - Introduction
- 27 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 230-231
Histoséminaire biopsies du péritoine - Introduction
- 22 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 235-236
Histoséminaire biopsies du péritoine. Réponses au pré-test
- 22 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 235-236
Histoséminaire biopsies du péritoine. Réponses au pré-test
- 15 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 232-234
Histoséminaire biopsies du péritoine. Prétest
- 15 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (4) , 232-234
Histoséminaire biopsies du péritoine. Prétest
- 10 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (3) , 204-209
Synovialosarcome primitif du rein : si tout était déjà dans les urines pyéliques ?
- 10 February 2024
- Published by Elsevier in Annales de Pathologie
- Vol. 44 (3) , 204-209
Synovialosarcome primitif du rein : si tout était déjà dans les urines pyéliques ?